The Claim
When apitegromab is combined with tirzepatide, the proportion of total weight loss attributable to lean mass decreases from 30.2% to 14.6%, while the proportion attributable to fat mass remains unchanged between treatment groups.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When apitegromab is taken with tirzepatide, a smaller percentage of the weight lost comes from muscle and a larger percentage comes from fat, compared to tirzepatide alone, with no change in total fat loss.
See the scientific wording
When combined with tirzepatide, apitegromab shifts the proportion of weight loss from lean mass to fat mass, reducing lean mass contribution from 30.2% to 14.6% of total weight loss, while fat mass loss remains similar between groups.
A drug blocks a natural signal that stops muscle growth, so when a person loses weight, their muscles don't break down as much. This means more of the weight lost comes from fat instead of muscle.
What the research says
1 studyWhen people take tirzepatide to lose weight, they often lose muscle too. But when they add apitegromab, they lose the same amount of total weight—but more of it comes from fat and less from muscle, helping them keep their strength.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.